Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

Injectable drugs require refrigeration when they are stored or transported, and the pill potentially opens up the market ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Rybelsus (semaglutide) is an oral medication used in combination with exercise and a healthy diet to help treat type 2 diabetes. It’s best taken on an empty stomach but isn’t known to interact ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Rybelsus (semaglutide) and Ozempic (semaglutide) are prescription drugs used to treat type 2 diabetes. Rybelsus comes as an oral tablet, while Ozempic comes as an injectable liquid solution.

Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial1.Data ...

Novo Nordisk’s diabetes pill Rybelsus, an oral semaglutide, reduced the risk of major heart-related events by 14% in adults with Type 2 diabetes and cardiovascular disease or chronic kidney ...

The FDA approval last Friday of Novo Nordisk’s Rybelsus as the first orally-active GLP-1 agonist is only the first challenge facing the company as it pursues its blockbuster sales targets for ...

Rybelsus is a pill form version of semaglutide – an FDA approved prescribed medication to manage blood sugar levels in patients with type 2 diabetes. Another effect that Rybelsus has is that it can ...

ASHLAND A local family physician and former Ashland School Board member pleaded guilty on Tuesday to federal charges related to the unlawful distribution of weight loss drugs on the heels of his ...

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...